CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Trial of Escalated Doses of Targeted Marrow Irradiation (TMI) Combined With Fludarabine and Busulfan as Conditioning Regimen for Allogeneic Hematopoietic Progenitor Cell Transplantation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02129582
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:11.597946+00:00
Published At: 2021-05-07T00:00:00+00:00
Record Updated At: 2021-05-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia", "Hematologic Malignancies", "Acute Lymphocytic Leukemia", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Multiple Myeloma", "Myelodysplastic Syndrome", "Chronic Lymphocytic Leukemia", "Chronic Myeloid Leukemia", "Myelofibrosis", "Myeloproliferative Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-05-07"
protocolSection.identificationModule.nctId: "NCT02129582"
protocolSection.identificationModule.officialTitle: "Phase I Trial of Escalated Doses of Targeted Marrow Irradiation (TMI) Combined With Fludarabine and Busulfan as Conditioning Regimen for Allogeneic Hematopoietic Progenitor Cell Transplantation"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.